157 related articles for article (PubMed ID: 32841450)
1. Evaluation of STAT3 decoy oligodeoxynucleotides' synergistic effects on radiation and/or chemotherapy in metastatic breast cancer cell line.
Johari B; Rahmati M; Nasehi L; Mortazavi Y; Faghfoori MH; Rezaeejam H
Cell Biol Int; 2020 Dec; 44(12):2499-2511. PubMed ID: 32841450
[TBL] [Abstract][Full Text] [Related]
2. Suppressing the metastatic properties of the breast cancer cells using STAT3 decoy oligodeoxynucleotides: A promising approach for eradication of cancer cells by differentiation therapy.
Rahmati M; Johari B; Kadivar M; Rismani E; Mortazavi Y
J Cell Physiol; 2020 Jun; 235(6):5429-5444. PubMed ID: 31912904
[TBL] [Abstract][Full Text] [Related]
3. Application of decoy oligodeoxynucleotides strategy for inhibition of cell growth and reduction of metastatic properties in nonresistant and erlotinib-resistant SW480 cell line.
Asadi Z; Fathi M; Rismani E; Bigdelou Z; Johari B
Cell Biol Int; 2021 May; 45(5):1001-1014. PubMed ID: 33377576
[TBL] [Abstract][Full Text] [Related]
4. Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides.
Johari B; Rezaeejam H; Moradi M; Taghipour Z; Saltanatpour Z; Mortazavi Y; Nasehi L
Mol Biol Rep; 2020 Sep; 47(9):6793-6805. PubMed ID: 32865703
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
[TBL] [Abstract][Full Text] [Related]
6. Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells.
Bigdelou Z; Mortazavi Y; Saltanatpour Z; Asadi Z; Kadivar M; Johari B
Mol Biol Rep; 2020 Mar; 47(3):1859-1869. PubMed ID: 32016633
[TBL] [Abstract][Full Text] [Related]
7. Targeting c-Myc with decoy oligodeoxynucleotide-loaded polycationic nanoparticles inhibits cell growth and induces apoptosis in cancer stem-like cells (NTERA-2).
Ghorbani R; Gharbavi M; Keshavarz B; Madanchi H; Johari B
Mol Biol Rep; 2024 May; 51(1):623. PubMed ID: 38710891
[TBL] [Abstract][Full Text] [Related]
8. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
9. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
Shi K; Fang Y; Gao S; Yang D; Bi H; Xue J; Lu A; Li Y; Ke L; Lin X; Jin X; Li M
J Control Release; 2018 Jun; 279():53-68. PubMed ID: 29655990
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α decoy oligodeoxynucleotides inhibit HIF-1α signaling and breast cancer proliferation.
Zhu X; Li Q; Li S; Chen B; Zou H
Int J Oncol; 2015 Jan; 46(1):215-22. PubMed ID: 25334080
[TBL] [Abstract][Full Text] [Related]
11. Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3.
Zhu Z; Yuan J; Xu X; Wei Y; Yang B; Zhao H
Neoplasia; 2021 Jan; 23(1):36-48. PubMed ID: 33217668
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous targeted inhibition of Sox2-Oct4 transcription factors using decoy oligodeoxynucleotides to repress stemness properties in mouse embryonic stem cells.
Johari B; Zargan J
Cell Biol Int; 2017 Dec; 41(12):1335-1344. PubMed ID: 28833847
[TBL] [Abstract][Full Text] [Related]
13. Myc Decoy Oligodeoxynucleotide Inhibits Growth and Modulates Differentiation of Mouse Embryonic Stem Cells as a Model of Cancer Stem Cells.
Johari B; Ebrahimi-Rad M; Maghsood F; Lotfinia M; Saltanatpouri Z; Teimoori-Toolabi L; Sharifzadeh Z; Karimipoor M; Kadivar M
Anticancer Agents Med Chem; 2017; 17(13):1786-1795. PubMed ID: 28403778
[TBL] [Abstract][Full Text] [Related]
14. Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells.
Johari B; Parvinzad Leilan M; Gharbavi M; Mortazavi Y; Sharafi A; Rezaeejam H
Oncol Res; 2023; 32(2):309-323. PubMed ID: 38186581
[TBL] [Abstract][Full Text] [Related]
15. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
16. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway.
Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809
[TBL] [Abstract][Full Text] [Related]
17. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
19. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
20. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
